These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 24847116)

  • 21. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
    Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
    Kwon M; Jang H; Kim EH; Roh JL
    Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
    Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
    Li J; Wang R; Kong Y; Broman MM; Carlock C; Chen L; Li Z; Farah E; Ratliff TL; Liu X
    Mol Cancer Ther; 2017 Mar; 16(3):469-479. PubMed ID: 28069876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
    Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
    J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
    Sui H; Shi C; Yan Z; Li H
    Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.
    Srivastava SK; Khan MA; Anand S; Zubair H; Deshmukh SK; Patel GK; Singh S; Andrews J; Wang B; Carter JE; Singh AP
    Br J Cancer; 2022 May; 126(8):1205-1214. PubMed ID: 34837075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
    Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
    Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
    J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response.
    Li Y; Luo K; Yin Y; Wu C; Deng M; Li L; Chen Y; Nowsheen S; Lou Z; Yuan J
    Nat Commun; 2017 Jun; 8():15752. PubMed ID: 28569838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
    Tang Z; Pilié PG; Geng C; Manyam GC; Yang G; Park S; Wang D; Peng S; Wu C; Peng G; Yap TA; Corn PG; Broom BM; Thompson TC
    Clin Cancer Res; 2021 Sep; 27(17):4898-4909. PubMed ID: 34168048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
    Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
    J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.
    Singh V; Jaiswal PK; Ghosh I; Koul HK; Yu X; De Benedetti A
    Int J Cancer; 2019 Aug; 145(4):1055-1067. PubMed ID: 30737777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells.
    Luo H; Liu Y; Li Y; Zhang C; Yu B; Shao C
    FASEB J; 2022 Sep; 36(9):e22495. PubMed ID: 35947121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
    Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
    Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
    Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
    J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.